Compare Stocks

→ Now Open: Crypto emergency update (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BTC ClearShares Piton Intermediate Fixed Income ETF	$90.46 -0.2%	$91.64	$98.48 ▼ $100.89	$29.40M	N/A	1,456 shs	402 shs
CTX Crescita Therapeutics	C$0.44 +4.8%	C$0.43	C$0.36 ▼ C$0.73	C$8.50M	1.66	18,188 shs	3,000 shs

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BTC ClearShares Piton Intermediate Fixed Income ETF	+0.31%	+0.01%	-1.16%	-1.41%	-8.55%
CTX Crescita Therapeutics	+3.57%	+3.57%	+10.13%	-19.44%	-33.08%

New crypto project uncovers 2,050% in 65 days (Ad)

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BTC ClearShares Piton Intermediate Fixed Income ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CTX Crescita Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BTC ClearShares Piton Intermediate Fixed Income ETF	0.00	N/A	N/A	N/A
CTX Crescita Therapeutics	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BTC ClearShares Piton Intermediate Fixed Income ETF	N/A	N/A	N/A	N/A	N/A	N/A
CTX Crescita Therapeutics	C$17.52M	0.49	C$0.36 per share	1.20	C$0.94 per share	0.46

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BTC ClearShares Piton Intermediate Fixed Income ETF	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CTX Crescita Therapeutics	-C$1.99M	-C$0.10	N/A	∞	N/A	-11.33%	-9.95%	-4.61%	5/9/2024 (Estimated)

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BTC ClearShares Piton Intermediate Fixed Income ETF	$0.02	0.02%	N/A	N/A	N/A
CTX Crescita Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BTC ClearShares Piton Intermediate Fixed Income ETF	N/A	N/A	N/A
CTX Crescita Therapeutics	6.66	3.80	2.29

Ownership

Institutional Ownership

Company	Institutional Ownership
BTC ClearShares Piton Intermediate Fixed Income ETF	N/A
CTX Crescita Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
BTC ClearShares Piton Intermediate Fixed Income ETF	N/A
CTX Crescita Therapeutics	10.32%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
BTC ClearShares Piton Intermediate Fixed Income ETF	147,000	325,000	N/A	Not Optionable
CTX Crescita Therapeutics	62	19.54 million	N/A	Not Optionable

CDY, BTC, CTX, and 1AD Headlines

Source	Headline
	CTNM Contineum Therapeutics, Inc. seekingalpha.com - April 18 at 9:49 AM
	Crescita Reports Q4 and Fiscal 2023 Results finance.yahoo.com - March 13 at 8:39 AM
	Crescita Therapeutics Inc CTX morningstar.com - February 17 at 12:14 AM
	Closing Bell: Crescita Therapeutics Inc up on Wednesday (CTX) theglobeandmail.com - December 14 at 12:12 AM
	Data backing prescription digital therapeutics found lacking in rigor, inclusivity statnews.com - November 11 at 8:31 PM
	Crescita Reports Third Quarter 2023 Results finance.yahoo.com - November 8 at 7:37 AM
	Closing Bell: Crescita Therapeutics Inc up on Thursday (CTX) theglobeandmail.com - November 4 at 1:14 PM
	Closing Bell: Crescita Therapeutics Inc down on Friday (CTX) theglobeandmail.com - September 30 at 12:35 AM
	Closing Bell: Crescita Therapeutics Inc flat on Tuesday (CTX) theglobeandmail.com - September 1 at 9:41 PM
	Crescita Reports Second Quarter 2023 Results finance.yahoo.com - August 9 at 9:05 AM
	Closing Bell: Crescita Therapeutics Inc flat on Monday (CTX) theglobeandmail.com - August 6 at 7:02 AM
	Closing Bell: Crescita Therapeutics Inc up on Friday (CTX) theglobeandmail.com - July 29 at 7:17 AM
	Closing Bell: Crescita Therapeutics Inc down on Monday (CTX) theglobeandmail.com - July 18 at 1:29 AM
	Subdued Growth No Barrier To Crescita Therapeutics Inc.'s (TSE:CTX) Price finance.yahoo.com - June 8 at 5:00 PM
	Croma-Pharma: Launch of topical anaesthetic Pliaglis® in Europe finance.yahoo.com - June 1 at 9:33 AM
	Crescita Reports First Quarter 2023 Results finance.yahoo.com - May 11 at 8:17 AM
	Closing Bell: Crescita Therapeutics Inc flat on Friday (CTX) theglobeandmail.com - April 15 at 1:08 AM
	Closing Bell: Crescita Therapeutics Inc up on Tuesday (CTX) theglobeandmail.com - April 12 at 8:28 AM
	Closing Bell: Crescita Therapeutics Inc flat on Thursday (CTX) theglobeandmail.com - April 11 at 8:10 AM
	Closing Bell: Crescita Therapeutics Inc flat on Wednesday (CTX) theglobeandmail.com - April 8 at 2:19 PM
	Closing Bell: Crescita Therapeutics Inc down on Wednesday (CTX) theglobeandmail.com - April 6 at 10:01 PM
	Crescita Therapeutics GAAP EPS of C$0.06, revenue of C$6M seekingalpha.com - March 18 at 12:33 AM
	Crescita Therapeutics Inc. Reports Q4 and Fiscal 2022 Results finanznachrichten.de - March 15 at 2:41 PM
	Crescita Therapeutics GAAP EPS of $0.06, revenue of $6M msn.com - March 15 at 2:41 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
5 Stocks in the Current Bull Market with Upside to Come
April 5, 2024 10:14 AM
View 5 Stocks in the Current Bull Market with Upside to Come
5 Top-Rated Dividend Stocks With Double-Digit Upside
March 25, 2024 11:19 AM
View 5 Top-Rated Dividend Stocks With Double-Digit Upside
All In: Is MicroStrategy Overleveraging Its Future on Bitcoin?
March 26, 2024 6:05 AM
View All In: Is MicroStrategy Overleveraging Its Future on Bitcoin?

All Headlines

Company Descriptions

ClearShares Piton Intermediate Fixed Income ETF

NYSEARCA:BTC

Crescita Therapeutics

TSE:CTX

Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers (MMPE) and DuraPeel for the development of topicals containing cannabis and hemp. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription portfolio offers dermocosmetic products, such as facial creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud brand; and provides medical aesthetics under Pro-Derm and Alyria brands, for non-invasive and minimally invasive procedures or skincare treatments. In addition, it distributes NCTF Boost 135 HA, a skin revitalization solution; Obagi Medical products; and ART FILLER, hyaluronic acid-based dermal fillers. The company has a commercialization license agreement with Cantabria Labs Inc.; and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial